Foghorn Therapeutics Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Foghorn Therapeutics is in Stage 4, the downtrend phase, now in week 3 (since Oct 6, 2026). It closed at $2.01, 71.6% below its 52-week high and below its 200-day average, which is falling.

$2.01

-1.47% today

$119M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is FHTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S1 15w

S2 18w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 5w → S4 10w → S1 15w → S2 5w → S3 10w → S2 18w → S3 6w → S4 21w → S1 9w → S2 6w → S3 6w → S4 7w → S1 2w → S2 11w → S3 6w → S4 10w → S1 4w → S2 5w → S3 2w → S4 2w current

Total tracked: 164 weeks across 21 stage runs.

FHTX among Biotechnology356th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…356	FHTXFoghorn Therapeutics Inc.	Stage 4 · wk 3	23	−48.1%

vs 52W High

-71.6%

$1.85 lo$7.07 hi

71.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-58.3%

200 DMA: $4.82 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.37x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-48.1%

-58.6%

-61.3%

YTD

-61.3%

-50.6%

Scan Membership

Breakout Watch

Latest: 2024-07-24

6 appearances in last 60 days. First seen: 2021-10-25.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.37x

2026-10-21S4

Wk 3 · Vol 0.92x

2026-10-20S4

Wk 3 · Vol 0.69x

2026-10-19S4

Wk 2 · Vol 0.55x

2026-10-16S4

Wk 2 · Vol 1.24x

2026-10-15S4

Wk 2 · Vol 0.44x

2026-10-14S4

Wk 2 · Vol 1.39x

2026-10-13S4

Wk 2 · Vol 1.12x

2026-10-12S4

Wk 1 · Vol 0.78x

2026-10-09S4

Wk 1 · Vol 0.87x

2026-10-08S4

Wk 1 · Vol 1.69x

2026-10-07S4

Wk 1 · Vol 1.30x

Moving averages & range

50 DMA

$4.16

200 DMA

$4.82

52W High

$7.07

52W Low

$1.85

5D Low

$1.85

Resistance levels (recent highs)

20d High

$3.57

60d High

$7.07

120d High

$7.07

250d High

$7.07

Next resistance

+77.6%

to 20d High

Dividend Yield

0.00%

P/B -1.5

Foghorn Therapeutics: quick answers

What stage is Foghorn Therapeutics in?

As of Oct 22, 2026, Foghorn Therapeutics (FHTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Foghorn Therapeutics in an uptrend?

No. Foghorn Therapeutics is in a Stage 4 downtrend. It trades 58.3% below its 200-day average, which is falling.

How far is Foghorn Therapeutics from its 52-week high?

Foghorn Therapeutics closed at $2.01 on Oct 22, 2026, 71.6% below its 52-week high of $7.07. Its 52-week low is $1.85.

How has Foghorn Therapeutics performed over the past year?

As of Oct 22, 2026, Foghorn Therapeutics is down 50.6% over the past year and down 61.3% so far in 2026.

Which sector and industry is Foghorn Therapeutics in?

Foghorn Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.